Novartis AG
COMPOSITIONS AND METHODS TO TREAT BIETTI CRYSTALLINE DYSTROPHY
Last updated:
Abstract:
Viral vectors to deliver a heterologous CYP4V2 gene to the retina, e.g., RPE cells of the retina, are provided herein to treat subjects with Bietti crystalline dystrophy.
Status:
Application
Type:
Utility
Filling date:
24 Feb 2020
Issue date:
19 May 2022